Pr Harald Schmidt will give a talk about Reactive oxygen-related diseases: therapeutic targets and emerging clinical indications
During Paris Redox World Congress 2016, Pr Harald Schmidt from Maastricht University, the Netherlands, will give a presentation about Reactive oxygen-related diseases: therapeutic targets and emerging clinical indications.
According to Pr Schmidt, numerous diseases and disease models have been suggested to be associated with oxidative stress; however very few if any have resulted in clinical application; some trials have been giant failures. Two innovations may provide a more successful and evidence-based way forward: the therapeutic move from focussing on ROS to their enzymatic sources and targets and the differentiation of physiological and pathological functions of these. Moreover a cluster of disease phenotypes within the so-called ‘diseasesome’ seems specifically linked to ROS-mediate pathologies. Here, he and his team, presents examples for such target validation within this cluster in diabetic end-organ damage and stroke, both linked by shared common redox mechanisms. These therapeutic advances will be backed-up by precision diagnostics that enable early detection, patient stratification, detecting target engagement and therapeutic monitoring.